This article was originally published in The Gray Sheet
Plans to use majority of $4.2 mil. in expected net proceeds from a stock offering for final development and preliminary sales and marketing of Sofceps, an obstetrical tractor designed to replace traditional steel obstetrical forceps. In a Securities and Exchange Commission filing for the proposed offering of 1 mil. shares at $5 each, the company notes that the product will be ready for human clinical trials no sooner than three months after the realization of the proceeds. Following the offering, which is being underwritten by Grady and Hatch & Co., there will be approximately 10.7 mil. shares outstanding. Recent bid and ask prices for the stock cited in the March filing were $3.13 and $3.63, respectively.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.